RS59269B1 - Antitela reaktivna na b7-h3, njihovi imunološki aktivni fragmenti i njihove upotrebe - Google Patents
Antitela reaktivna na b7-h3, njihovi imunološki aktivni fragmenti i njihove upotrebeInfo
- Publication number
- RS59269B1 RS59269B1 RSP20191067A RS59269B1 RS 59269 B1 RS59269 B1 RS 59269B1 RS P20191067 A RSP20191067 A RS P20191067A RS 59269 B1 RS59269 B1 RS 59269B1
- Authority
- RS
- Serbia
- Prior art keywords
- active fragments
- immunologically active
- antibodies reactive
- antibodies
- reactive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31069510P | 2010-03-04 | 2010-03-04 | |
US31069210P | 2010-03-04 | 2010-03-04 | |
US31105710P | 2010-03-05 | 2010-03-05 | |
EP11751204.6A EP2542256B1 (en) | 2010-03-04 | 2011-03-01 | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
PCT/US2011/026689 WO2011109400A2 (en) | 2010-03-04 | 2011-03-01 | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
RS59269B1 true RS59269B1 (sr) | 2019-10-31 |
Family
ID=44542802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP20191067 RS59269B1 (sr) | 2010-03-04 | 2011-03-01 | Antitela reaktivna na b7-h3, njihovi imunološki aktivni fragmenti i njihove upotrebe |
Country Status (41)
Families Citing this family (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2707152T3 (es) * | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
KR101614494B1 (ko) | 2008-04-02 | 2016-04-22 | 마크로제닉스, 인크. | Bcr-복합체-특이적 항체 및 그것의 사용 방법 |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
LT2542256T (lt) * | 2010-03-04 | 2019-10-25 | Macrogenics Inc | Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas |
SG187682A1 (en) * | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
KR102125672B1 (ko) * | 2011-04-25 | 2020-06-23 | 다이이찌 산쿄 가부시키가이샤 | 항 b7-h3항체 |
CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
CN104470536A (zh) | 2012-03-03 | 2015-03-25 | 免疫基因公司 | 工程化的抗体-干扰素突变体融合分子 |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
DK2956482T3 (en) | 2013-02-14 | 2017-10-16 | Innate Pharma | TREATMENT OF PERFECT T cell lymphoma |
EP3521312B1 (en) | 2013-02-20 | 2021-04-07 | Innate Pharma | A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
IL275376B2 (en) | 2013-03-11 | 2024-01-01 | Genzyme Corp | Polypeptides with hyperglycosidic bonds |
WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
BR112015025347A2 (pt) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer |
US20160184399A1 (en) | 2013-08-08 | 2016-06-30 | Cytune Pharma | Combined pharmaceutical composition |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
NZ756750A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
CA2925421C (en) | 2013-09-24 | 2023-08-29 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
AU2014342182B2 (en) | 2013-10-30 | 2020-05-14 | Eberhard Karls Universitat Tubingen | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta TCR -binding polypeptide |
SG11201605097SA (en) | 2013-12-24 | 2016-07-28 | Bristol Myers Squibb Co | Tricyclic compounds as anticancer agents |
CN106604740A (zh) * | 2014-02-14 | 2017-04-26 | 宏观基因有限公司 | 用于治疗血管化癌症的改进的方法 |
US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
KR102345173B1 (ko) | 2014-03-14 | 2021-12-29 | 이나뜨 파르마 에스.에이. | 증가된 안정성을 가진 인간화 항체 |
CN116333148A (zh) | 2014-03-19 | 2023-06-27 | 建新公司 | 靶向模块的位点特异性糖工程化 |
JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
EP3149040A1 (en) * | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti-b7-h3 antibodies and diagnostic uses thereof |
AP2016009586A0 (en) | 2014-05-29 | 2016-11-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
ES2755395T3 (es) | 2014-06-06 | 2020-04-22 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos |
MX2016015610A (es) | 2014-06-06 | 2017-07-13 | Flexus Biosciences Inc | Agentes inmunorreguladores. |
JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
EP3160994A2 (en) | 2014-06-27 | 2017-05-03 | Innate Pharma | Multispecific antigen binding proteins |
SG11201700074YA (en) | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
DK3180018T3 (da) | 2014-08-12 | 2019-10-28 | Massachusetts Inst Technology | Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein |
EP3186277B1 (en) * | 2014-08-27 | 2020-10-07 | Memorial Sloan Kettering Cancer Center | Antibodies, compositions, and uses |
WO2016030488A1 (en) | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
JP6613304B2 (ja) * | 2014-09-17 | 2019-12-04 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗cd276抗体(b7h3) |
CA2964123C (en) | 2014-10-09 | 2023-09-05 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
CA2959841A1 (en) | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
EP3215141A4 (en) | 2014-11-05 | 2018-06-06 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10100129B2 (en) | 2014-11-21 | 2018-10-16 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | TGFβR拮抗劑 |
AU2015369683B2 (en) | 2014-12-23 | 2020-12-10 | Bristol-Myers Squibb Company | Antibodies to TIGIT |
US9884868B2 (en) | 2015-03-02 | 2018-02-06 | Rigel Pharmaceuticals, Inc. | TGF-beta inhibitors |
BR112017020999A2 (pt) | 2015-04-03 | 2018-07-03 | Bristol-Myers Squibb Company | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer |
TW201642897A (zh) | 2015-04-08 | 2016-12-16 | F 星生物科技有限公司 | Her2結合劑治療 |
LT3283527T (lt) | 2015-04-13 | 2021-03-25 | Five Prime Therapeutics, Inc. | Kompleksinė terapija vėžio gydymui |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
TW201717935A (zh) | 2015-06-03 | 2017-06-01 | 波士頓生醫公司 | 用於治療癌症的組成物和方法 |
CA2990511A1 (en) | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific antigen binding proteins |
EP3313881A1 (en) | 2015-06-23 | 2018-05-02 | Innate Pharma | Multispecific nk engager proteins |
MX2017016863A (es) * | 2015-06-25 | 2018-09-06 | Advanced Accelerator Applications | Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina. |
JP2018526977A (ja) | 2015-06-29 | 2018-09-20 | ザ ロックフェラー ユニヴァーシティ | アゴニスト活性が増強されたcd40に対する抗体 |
KR20180034548A (ko) | 2015-07-28 | 2018-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
CN108025051B (zh) * | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
MX2018001227A (es) * | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
CN107921130A (zh) * | 2015-08-17 | 2018-04-17 | 宏观基因有限公司 | 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途 |
WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
EP3347375B1 (en) * | 2015-09-10 | 2020-12-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd276 chimeric antigen receptors |
AU2016329057A1 (en) | 2015-09-30 | 2018-04-12 | Janssen Biotech, Inc. | Antagonistic antibodies specifically binding human CD40 and methods of use |
WO2017062619A2 (en) * | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
US10894830B2 (en) | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
WO2017083354A1 (en) * | 2015-11-10 | 2017-05-18 | Yale University | Compositions and methods for treating autoimmune diseases and cancers |
SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
CA3004794A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
US20200254118A1 (en) * | 2015-12-02 | 2020-08-13 | Sunitha Bachawal | Breast cancer detection using b7-h3-targeted molecular imaging |
WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
EP3390406A1 (en) | 2015-12-15 | 2018-10-24 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
US20190000989A1 (en) * | 2016-01-11 | 2019-01-03 | STC Biologics Inc. | Bispecific targeting agents and methods for their preparation |
BR112018067368A2 (pt) | 2016-03-04 | 2019-01-15 | Bristol-Myers Squibb Company | terapia de combinação com anticorpos anti-cd73 |
SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
CA3016765A1 (en) | 2016-03-15 | 2017-09-21 | Innate Pharma | Anti-mica antibodies |
MX2018012433A (es) * | 2016-04-15 | 2019-03-01 | Macrogenics Inc | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos. |
WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
JP2019516687A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
JP2019516682A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
WO2017214322A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214339A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CN116284404A (zh) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
MY200602A (en) | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
US20190292179A1 (en) | 2016-07-21 | 2019-09-26 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
MA45941A (fr) | 2016-08-12 | 2019-06-19 | Janssen Biotech Inc | Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation |
US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
KR20230173745A (ko) | 2016-10-21 | 2023-12-27 | 이나뜨 파르마 에스.에이. | 항-kir3dl2 작용제에 의한 치료 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
CN110167591B (zh) | 2016-12-23 | 2023-09-26 | 宏观基因有限公司 | Adam9结合分子及使用其的方法 |
LT3558391T (lt) | 2016-12-23 | 2022-07-11 | Immunogen, Inc. | Imunokonjugatai, kurių taikinys yra adam9, ir jų naudojimo būdai |
EP3559032A1 (en) | 2016-12-23 | 2019-10-30 | Innate Pharma | Heterodimeric antigen binding proteins |
US11046764B2 (en) | 2017-01-03 | 2021-06-29 | Trellis Bioscience, Llc | Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3 |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
WO2018132516A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
PL3570844T3 (pl) | 2017-01-20 | 2024-02-26 | Arcus Biosciences, Inc. | Azolopirymidyna do leczenia zaburzeń związanych z nowotworami |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CA3053222A1 (en) * | 2017-02-10 | 2018-08-16 | Genmab B.V. | Polypeptide variants and uses thereof |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
KR102585848B1 (ko) | 2017-02-24 | 2023-10-11 | 마크로제닉스, 인크. | Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도 |
CN109843927B (zh) * | 2017-03-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
FR3064007A1 (fr) * | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
US20200031944A1 (en) | 2017-03-31 | 2020-01-30 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
JP7158403B2 (ja) | 2017-03-31 | 2022-10-21 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | B7-h3抗体、その抗原結合フラグメント、及びそれらの医学的使用 |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
CA3059939A1 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
WO2018213377A1 (en) | 2017-05-17 | 2018-11-22 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
EP3641814A4 (en) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF |
CN109097366A (zh) * | 2017-06-21 | 2018-12-28 | 黄海东 | 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用 |
BR112019027259A2 (pt) | 2017-06-30 | 2020-07-14 | Bristol-Myers Squibb Company | formas amorfas e cristalinas de inibidores da ido |
CN110997691B (zh) | 2017-07-28 | 2023-11-07 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
JP7269917B2 (ja) | 2017-08-17 | 2023-05-09 | イケナ オンコロジー, インコーポレイテッド | Ahr阻害剤およびその使用 |
JP7209697B2 (ja) | 2017-08-31 | 2023-01-20 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
ES2904317T3 (es) | 2017-08-31 | 2022-04-04 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
CN111032672A (zh) | 2017-08-31 | 2020-04-17 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
KR101912587B1 (ko) * | 2017-09-14 | 2018-10-30 | 펌텍코리아(주) | 스포이드형 이종 내용물 혼합 용기 |
EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
IL307995A (en) | 2017-09-22 | 2023-12-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
CN111344297B (zh) | 2017-10-10 | 2023-10-20 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019079261A1 (en) | 2017-10-16 | 2019-04-25 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
EP3704159A1 (en) | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
US11166959B2 (en) | 2017-11-06 | 2021-11-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as HPK1 inhibitors |
US20200325232A1 (en) | 2017-11-21 | 2020-10-15 | Innate Pharma | Multispecific antigen binding proteins |
SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
IL304055A (en) | 2017-12-26 | 2023-08-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
KR20200103761A (ko) | 2017-12-27 | 2020-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN111886255A (zh) | 2018-01-12 | 2020-11-03 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
CN111867581B (zh) | 2018-01-29 | 2023-12-26 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
CN118005640A (zh) | 2018-01-29 | 2024-05-10 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
BR112020016190A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpos direcionando o receptor nkg2d |
US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
CN111971304A (zh) | 2018-03-21 | 2020-11-20 | 戊瑞治疗有限公司 | 在酸性pH结合至VISTA的抗体 |
KR20200142542A (ko) | 2018-04-12 | 2020-12-22 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법 |
AU2019255196A1 (en) | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
WO2019225787A1 (ko) * | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
BR112020025346A2 (pt) | 2018-06-26 | 2021-05-25 | Immunogen, Inc. | imunoconjugados que alvejam adam9 e métodos de uso dos mesmos |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
MX2021000009A (es) | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
PE20210687A1 (es) | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
US20210355113A1 (en) | 2018-07-23 | 2021-11-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CA3107079A1 (en) | 2018-07-27 | 2020-01-30 | Arcus Biosciences, Inc. | Pyridone a2r antagonists |
CN112789291A (zh) * | 2018-08-08 | 2021-05-11 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
WO2020047257A1 (en) * | 2018-08-31 | 2020-03-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions comprising b7h3 chimeric antigen receptors |
CN110950953B (zh) * | 2018-09-26 | 2022-05-13 | 福州拓新天成生物科技有限公司 | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 |
BR112021004383A2 (pt) | 2018-09-28 | 2021-08-03 | Massachusetts Institute Of Technology | proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito |
EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
CN110305213B (zh) * | 2018-11-09 | 2023-03-10 | 泰州复旦张江药业有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
WO2020094120A1 (zh) * | 2018-11-09 | 2020-05-14 | 上海复旦张江生物医药股份有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
US20220119529A1 (en) * | 2018-11-22 | 2022-04-21 | Suzhou Kanova Biopharmaceutical Co., Ltd. | An anti-b7-h3 antibody |
JP2022516401A (ja) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
CN113260703A (zh) * | 2018-12-24 | 2021-08-13 | 黄海东 | 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用 |
CN109851673B (zh) * | 2019-01-22 | 2023-07-25 | 苏州旭光科星抗体生物科技有限公司 | 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒 |
AU2020210710A1 (en) | 2019-01-22 | 2021-07-29 | Innate Pharma | Treatment of T cell lymphoma |
US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
JP2022528887A (ja) | 2019-04-02 | 2022-06-16 | バイスクルテクス・リミテッド | バイシクルトキシンコンジュゲートおよびその使用 |
US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
AU2020299305A1 (en) * | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-B7-H3 antibody and methods of use thereof |
KR20210006637A (ko) * | 2019-07-09 | 2021-01-19 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技(成都)有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
WO2021050964A1 (en) | 2019-09-13 | 2021-03-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
WO2021052307A1 (zh) * | 2019-09-16 | 2021-03-25 | 南京圣和药业股份有限公司 | 一种抗b7-h3抗体及其应用 |
JP2022548292A (ja) | 2019-09-19 | 2022-11-17 | ブリストル-マイヤーズ スクイブ カンパニー | 酸性pHでVISTAと結合する抗体 |
MX2022005839A (es) | 2019-11-19 | 2022-06-09 | Bristol Myers Squibb Co | Compuestos utiles como inhibidores de la proteina helios. |
WO2021101349A1 (ko) * | 2019-11-21 | 2021-05-27 | 에이비엘바이오 주식회사 | Ror1 및 b7-h3에 결합하는 항체, 이를 포함하는 항체-약물 접합체 및 그 용도 |
WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
CN111000978B (zh) * | 2019-11-22 | 2023-03-10 | 中山大学附属第五医院 | Tlt-2在制备治疗结核病药物中的应用 |
IL293357A (en) | 2019-11-26 | 2022-07-01 | Bristol Myers Squibb Co | Salts/crystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
JP2023502531A (ja) | 2019-11-26 | 2023-01-24 | イケナ オンコロジー, インコーポレイテッド | 多形カルバゾール誘導体およびその使用 |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
CN114846015A (zh) | 2019-12-23 | 2022-08-02 | 百时美施贵宝公司 | 用作t细胞激活剂的经取代的杂芳基化合物 |
US20230094758A1 (en) | 2019-12-23 | 2023-03-30 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
IL294269A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substitute quinolinyl piperazine compounds are useful as t-cell activators |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
EP4121456A1 (en) | 2020-03-18 | 2023-01-25 | Genmab A/S | Antibodies binding to b7h4 |
TW202200543A (zh) | 2020-03-19 | 2022-01-01 | 美商凱麥拉醫療公司 | Mdm2降解劑及其用途 |
BR112022018600A2 (pt) | 2020-03-19 | 2022-11-08 | Arcus Biosciences Inc | Compostos, composição farmacêutica, método de tratamento de uma doença e combinação |
TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
CN113527487A (zh) * | 2020-04-22 | 2021-10-22 | 复星凯特生物科技有限公司 | 抗人b7-h3的单克隆抗体及其应用 |
CA3176246A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
AU2021284808A1 (en) * | 2020-06-04 | 2022-12-15 | Y-Mabs Therapeutics, Inc. | Anti-B7H3 antibodies for the treatment of cancer |
CN116249717A (zh) * | 2020-06-24 | 2023-06-09 | 普罗塞纳生物科学有限公司 | 识别分拣蛋白的抗体 |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
CN112851812B (zh) * | 2020-06-30 | 2021-09-14 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
CA3187255A1 (en) | 2020-07-30 | 2022-02-03 | Duncan Walker | Methods of treating mutant lymphomas |
CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
CN116063550A (zh) * | 2020-09-02 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
US20230416382A1 (en) | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
AU2021390121A1 (en) * | 2020-12-02 | 2023-06-29 | Mabwell (shanghai) Bioscience Co., Ltd. | Anti-human b7-h3 antibody and application thereof |
EP4269435A1 (en) * | 2020-12-23 | 2023-11-01 | Innovent Biologics (Singapore) Pte. Ltd. | Anti-b7-h3 antibody and uses thereof |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
US20240109899A1 (en) | 2021-02-04 | 2024-04-04 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
KR20230145038A (ko) | 2021-02-09 | 2023-10-17 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | 생물활성 물질 접합체, 이의 제조방법 및 이의 용도 |
AU2022221124A1 (en) | 2021-02-12 | 2023-08-03 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
WO2022174269A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
EP4301756A1 (en) | 2021-03-05 | 2024-01-10 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
US20240165256A1 (en) | 2021-03-08 | 2024-05-23 | Immunogen, Inc. | Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer |
KR20220134462A (ko) | 2021-03-26 | 2022-10-05 | 세라노틱스(주) | B7-h3 항체 또는 이의 항원 결합 단편 및 이의 용도 |
CA3207652A1 (en) | 2021-03-26 | 2022-09-29 | Stephanie Cornen | Cytokine anchors for nkp46-binding nk cell engager proteins |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
AU2022253450A1 (en) | 2021-04-05 | 2023-11-16 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
CN117751145A (zh) * | 2021-04-28 | 2024-03-22 | 礼进生物医药科技(上海)有限公司 | 包括抗b7h3结合分子的双特异性抗体 |
CA3214582A1 (en) | 2021-05-07 | 2022-11-10 | Martin SAHLIN | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
TW202313603A (zh) | 2021-05-21 | 2023-04-01 | 美商阿克思生物科學有限公司 | Axl抑制劑化合物 |
KR20240019786A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
CN113683697B (zh) * | 2021-08-27 | 2022-06-17 | 上海祥耀生物科技有限责任公司 | 抗b7-h3抗体、其制备方法及用途 |
KR20230035508A (ko) | 2021-08-27 | 2023-03-14 | 세라노틱스(주) | B7-H3 및 TGFβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도 |
TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
CN116589586B (zh) * | 2022-02-25 | 2024-02-02 | 南京蓬勃生物科技有限公司 | 针对人b7-h3的抗体及其变体 |
WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
CN116396388A (zh) * | 2022-08-26 | 2023-07-07 | 四川大学 | 一种抗b7-h3抗体及其应用 |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
WO2024086718A1 (en) | 2022-10-20 | 2024-04-25 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
WO2024092073A1 (en) * | 2022-10-26 | 2024-05-02 | Abbratech Inc. | Chimeric antibodies and methods of making and using same |
CN116199779B (zh) * | 2022-12-08 | 2023-08-11 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 |
Family Cites Families (245)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (sr) | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4752601A (en) | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5185432A (en) | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US5185462A (en) | 1987-01-08 | 1993-02-09 | Bp Chemicals Limited | Production of carboxylic acids and esters thereof |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
FR2626882B1 (fr) | 1988-02-08 | 1991-11-08 | Ire Celltarg Sa | Conjugues de derives de vinca comportant une chaine detergente en position c-3 |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
KR0149012B1 (ko) | 1988-05-27 | 1998-08-17 | 쇼트보르그 레기날드 데 | 사람 f크롬 수용체 iii |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
DE68928427T2 (de) | 1988-09-15 | 1998-06-04 | Univ Columbia | Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
GB8916400D0 (en) | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5364930A (en) | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5843749A (en) | 1991-07-26 | 1998-12-01 | Regeneron Pharmaceuticals, Inc. | Ehk and Ror tyrosine kinases |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
EP0682710B1 (en) | 1993-02-10 | 2003-10-29 | Unilever Plc | Isolation process using immobilized proteins with specific binding capacities |
US5877396A (en) | 1993-04-23 | 1999-03-02 | Sloan Kettering Institute For Cancer Research | Mice mutant for functional Fc receptors and method of treating autoimmune diseases |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
AU7516694A (en) | 1993-07-30 | 1995-02-28 | Affymax Technologies N.V. | Biotinylation of proteins |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
NZ276943A (en) | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
AU722247B2 (en) | 1994-08-12 | 2000-07-27 | Edward E. Timm | Spinal support system for seating |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
JP2001506967A (ja) | 1996-08-02 | 2001-05-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法 |
US6025485A (en) | 1997-02-14 | 2000-02-15 | Arcaris, Inc. | Methods and compositions for peptide libraries displayed on light-emitting scaffolds |
US6339069B1 (en) | 1996-10-15 | 2002-01-15 | Elan Pharmaceuticalstechnologies, Inc. | Peptide-lipid conjugates, liposomes and lipsomal drug delivery |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6090381A (en) | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6972323B1 (en) * | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
WO1999019362A1 (en) | 1997-10-15 | 1999-04-22 | Medarex, Inc. | BISPECIFIC MOLECULES DIRECTED TO TUMOR ASSOCIATED GLYCOPROTEIN-72 AND Fc RECEPTOR |
CA2248971A1 (en) | 1997-10-31 | 1999-04-30 | Kyowa Hakko Kogyo Co., Ltd. | .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use |
IL137919A0 (en) | 1998-02-17 | 2001-10-31 | Medarex Inc | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
EP1060194A1 (en) | 1998-02-25 | 2000-12-20 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
NZ507435A (en) | 1998-03-10 | 2003-12-19 | Genentech Inc | Novel polypeptides and nucleic acids with homology to cornichon |
US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
EP1151012A4 (en) * | 1998-11-19 | 2003-01-08 | Smithkline Beecham Corp | ANTAGONIST ANTIBODIES OF RHAMM |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL350909A1 (en) | 1999-02-12 | 2003-02-10 | Genetics Inst | Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
WO2000068266A1 (en) | 1999-05-11 | 2000-11-16 | Eli Lilly And Company | Amyloid precursor protein protease and related nucleic acid compounds |
EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
CA2389916A1 (en) | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
US6429303B1 (en) | 1999-09-03 | 2002-08-06 | Curagen Corporation | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
DE60032633T2 (de) | 1999-11-24 | 2007-10-04 | Immunogen Inc., Cambridge | Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung |
US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
CZ20023203A3 (cs) | 2000-03-24 | 2003-08-13 | Micromet Ag | Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D |
US20060154313A1 (en) | 2000-04-13 | 2006-07-13 | Immunex Corporation | Human B7 polypeptide B7-H3A |
JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
CA2412377A1 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP1892251A3 (en) | 2000-06-06 | 2008-12-31 | Brystol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
US6891030B2 (en) * | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EP1327638A4 (en) | 2000-09-12 | 2004-09-29 | Kirin Brewery | NEW WALL MEMBRANE OF DENDRITIC CELLS AND THEIR USE |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
CA2423843A1 (en) | 2000-10-18 | 2002-04-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
JP4229704B2 (ja) | 2001-04-18 | 2009-02-25 | ダイアックス、コープ | Fc領域ポリペプチドの結合分子 |
DE60230736D1 (de) | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
WO2003024191A2 (en) | 2001-09-21 | 2003-03-27 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
EP1439857B1 (en) | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
US7148038B2 (en) | 2001-10-16 | 2006-12-12 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
CN1250920C (zh) * | 2001-10-17 | 2006-04-12 | 罗伯特·福尔克 | 推拉门装置 |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
AU2002359851A1 (en) | 2001-12-21 | 2003-07-30 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
AU2003206264A1 (en) | 2002-02-07 | 2003-09-02 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | MODULATING TOLERANCE BY MODULATING FcGammaRIIB RECEPTOR SIGNALLING |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
JP2006506323A (ja) | 2002-04-12 | 2006-02-23 | レイヴェン バイオテクノロジーズ, インコーポレイテッド | インテグリンα−v−β−6に結合する抗体およびその使用方法 |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
WO2003093443A2 (en) | 2002-05-03 | 2003-11-13 | Raven Biotechnologies, Inc. | Alcam and alcam modulators |
EP1519956B1 (en) | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US7351803B2 (en) | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
EP1565489B1 (en) * | 2002-06-19 | 2010-11-17 | Raven Biotechnologies, Inc. | Internalizing antibodies specific for the RAAG10 cell surface target |
KR101115797B1 (ko) | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법 |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20090017023A1 (en) | 2002-08-14 | 2009-01-15 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
US20050058661A1 (en) | 2002-10-18 | 2005-03-17 | Sykes Kathryn F. | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia |
EP1581096A4 (en) | 2002-11-13 | 2006-06-21 | Raven Biotechnologies Inc | ANTIGEN PIPA AND BINDING ANTIBODIES THEREOF |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2052713A3 (en) | 2003-01-13 | 2009-05-20 | Macrogenics, Inc. | Soluble FcgammaR fusion proteins and methods of use thereof |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2005018669A1 (en) | 2003-08-18 | 2005-03-03 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
KR20060079236A (ko) | 2003-09-18 | 2006-07-05 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | Kid3 및 그것과 결합하는 kid3 항체 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
KR101149242B1 (ko) | 2004-01-12 | 2012-05-25 | 어플라이드 몰리큘라 에볼류션, 인코포레이티드 | Fc 영역 변이체 |
MXPA06011425A (es) | 2004-03-31 | 2007-03-12 | Johnson & Johnson | Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos. |
WO2005115452A2 (en) | 2004-04-16 | 2005-12-08 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
EP1761563A4 (en) | 2004-05-10 | 2008-05-14 | Macrogenics Inc | HUMANIZED gamma RIIB SPECIFIC ANTIBODIES AND METHODS OF USE |
CA2569692C (en) | 2004-06-07 | 2015-07-21 | Raven Biotechnologies, Inc. | Transferrin receptor antibodies |
BRPI0512235A (pt) | 2004-06-18 | 2008-02-19 | Ambrx Inc | polipeptìdeos ligadores de antìgenos e seus usos |
KR20180091967A (ko) | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
ES2534288T3 (es) * | 2004-08-03 | 2015-04-21 | Innate Pharma | Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3 |
EP1776384B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant fc regions |
ZA200701783B (en) | 2004-09-02 | 2009-10-28 | Genentech Inc | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
WO2006066078A2 (en) | 2004-12-15 | 2006-06-22 | Magrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
WO2006076584A2 (en) | 2005-01-12 | 2006-07-20 | Raven Biotechnologies, Inc. | Kid31 and antibodies that bind thereto |
CA2596115A1 (en) | 2005-01-31 | 2006-08-10 | Raven Biotechnologies, Inc. | Luca2 and antibodies that bind thereto |
US20060171952A1 (en) | 2005-02-02 | 2006-08-03 | Mather Jennie P | JAM-3 and antibodies that bind thereto |
NZ556561A (en) | 2005-02-02 | 2011-08-26 | Macrogenics West Inc | Adam-9 modulators |
US7572896B2 (en) | 2005-02-03 | 2009-08-11 | Raven Biotechnologies, Inc. | Antibodies to oncostatin M receptor |
CA2597198C (en) | 2005-02-04 | 2016-06-21 | Raven Biotechnologies, Inc. | Antibodies that bind to epha2 and methods of use thereof |
US20060193849A1 (en) | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
SG163615A1 (en) | 2005-07-11 | 2010-08-30 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
BRPI0612814A2 (pt) | 2005-07-11 | 2017-06-20 | Macrogenics Inc | anticorpo, métodos para redução e para tratamento de uma resposta imune prejudicial em um mamífero, proteína de ligação ao cd16a, e, método para redução dos efeitos colaterais de primeira dose em um paciente |
EP2573114B1 (en) * | 2005-08-10 | 2016-03-30 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
AU2006312148B2 (en) | 2005-11-07 | 2012-04-12 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
FR2894982A1 (fr) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス,インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
MX2008015524A (es) * | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
MX2008015771A (es) | 2006-06-14 | 2009-01-27 | Macrogenics Inc | Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida. |
CA2656224C (en) | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
BRPI0712953B8 (pt) | 2006-06-30 | 2021-05-25 | Novo Nordisk As | anticorpos anti-nkg2a, seu uso, e composição farmacêutica |
US20080112961A1 (en) | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
US7718774B2 (en) | 2006-11-08 | 2010-05-18 | Macrogenics, Inc. | TES7 and antibodies that bind thereto |
US7992748B2 (en) | 2006-11-17 | 2011-08-09 | North Safety Products, Inc. | Earplug dispenser |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
MX2009006082A (es) * | 2006-12-08 | 2009-08-18 | Lexicon Pharmaceuticals Inc | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). |
EP2094302A4 (en) | 2006-12-21 | 2010-12-08 | Macrogenics Inc | METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY |
EP2109668A4 (en) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | HUMAN CANCER STEM CELLS |
WO2008116219A2 (en) | 2007-03-22 | 2008-09-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
FR2916763B1 (fr) | 2007-05-31 | 2013-11-15 | Biomerieux Sa | Nouveaux substrats de peptidase |
EP2158221B1 (en) * | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
EP2178914A2 (en) | 2007-08-15 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
BRPI0818963A2 (pt) | 2007-11-30 | 2015-05-05 | Bristol Myers Squibb Co | Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo |
EP2234641B1 (en) | 2008-01-03 | 2015-08-19 | Genmab A/S | Monoclonal antibodies against cd32b |
EP2247304B1 (en) | 2008-04-02 | 2016-05-25 | MacroGenics, Inc. | Her2/neu-specific antibodies and methods of using same |
KR101614494B1 (ko) | 2008-04-02 | 2016-04-22 | 마크로제닉스, 인크. | Bcr-복합체-특이적 항체 및 그것의 사용 방법 |
US20090262732A1 (en) | 2008-04-16 | 2009-10-22 | Barry Wood | Data Communications Network |
EP2282770B1 (en) | 2008-06-04 | 2018-03-07 | MacroGenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
JP2012501178A (ja) | 2008-08-26 | 2012-01-19 | マクロジェニクス,インコーポレーテッド | T細胞受容体抗体およびその使用方法 |
HUE043084T2 (hu) * | 2008-12-19 | 2019-08-28 | Macrogenics Inc | Kovalens diatestek és alkalmazásaik |
EP2399130A4 (en) * | 2009-02-20 | 2012-06-06 | Wayne John Cancer Inst | ASSAY OF B7-H3 ANTIBODY-COUPLED BEADS FOR THE ISOLATION AND DETECTION OF CIRCULATING TUMOR CELLS IN THE BODILY FLUIDS OF MELANOMA AND BREAST CANCER PATIENTS |
ES2672121T3 (es) | 2009-10-07 | 2018-06-12 | Macrogenics, Inc. | Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso |
LT2542256T (lt) * | 2010-03-04 | 2019-10-25 | Macrogenics Inc | Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas |
US8802091B2 (en) * | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
SG187682A1 (en) | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
CN106604740A (zh) * | 2014-02-14 | 2017-04-26 | 宏观基因有限公司 | 用于治疗血管化癌症的改进的方法 |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2011
- 2011-03-01 LT LT11751204T patent/LT2542256T/lt unknown
- 2011-03-01 KR KR1020127024855A patent/KR101828570B1/ko active IP Right Grant
- 2011-03-01 US US13/581,340 patent/US9150656B2/en active Active
- 2011-03-01 NZ NZ705128A patent/NZ705128A/en unknown
- 2011-03-01 PE PE2017000721A patent/PE20170779A1/es not_active Application Discontinuation
- 2011-03-01 ES ES11751204T patent/ES2742351T3/es active Active
- 2011-03-01 JP JP2012556173A patent/JP5998060B2/ja active Active
- 2011-03-01 AU AU2011223782A patent/AU2011223782B2/en active Active
- 2011-03-01 BR BR112012022210-4A patent/BR112012022210B1/pt active IP Right Grant
- 2011-03-01 ME MEP-2019-216A patent/ME03447B/me unknown
- 2011-03-01 MX MX2012010201A patent/MX345232B/es active IP Right Grant
- 2011-03-01 MY MYPI2012003933A patent/MY156358A/en unknown
- 2011-03-01 GE GEAP201113262A patent/GEP201706660B/en unknown
- 2011-03-01 EP EP11751204.6A patent/EP2542256B1/en active Active
- 2011-03-01 MA MA35203A patent/MA34062B1/fr unknown
- 2011-03-01 RS RSP20191067 patent/RS59269B1/sr unknown
- 2011-03-01 ES ES15184260T patent/ES2895480T3/es active Active
- 2011-03-01 SG SG2012064671A patent/SG183847A1/en unknown
- 2011-03-01 NZ NZ701539A patent/NZ701539A/en unknown
- 2011-03-01 HU HUE11751204A patent/HUE045487T2/hu unknown
- 2011-03-01 WO PCT/US2011/026689 patent/WO2011109400A2/en active Application Filing
- 2011-03-01 PT PT11751204T patent/PT2542256T/pt unknown
- 2011-03-01 EA EA201270734A patent/EA030226B1/ru unknown
- 2011-03-01 BR BR122016002916A patent/BR122016002916B8/pt active IP Right Grant
- 2011-03-01 PE PE2012001393A patent/PE20130479A1/es active IP Right Grant
- 2011-03-01 CA CA2791658A patent/CA2791658C/en active Active
- 2011-03-01 CN CN201610635184.8A patent/CN106279416B/zh active Active
- 2011-03-01 EP EP15184260.6A patent/EP2982380B1/en active Active
- 2011-03-01 DK DK11751204.6T patent/DK2542256T3/da active
- 2011-03-01 SI SI201131764T patent/SI2542256T1/sl unknown
- 2011-03-01 SG SG10201604336VA patent/SG10201604336VA/en unknown
- 2011-03-01 GE GEAP201112866A patent/GEP20166442B/en unknown
- 2011-03-01 PH PH12018501083A patent/PH12018501083A1/en unknown
- 2011-03-01 PL PL11751204T patent/PL2542256T3/pl unknown
- 2011-03-01 NZ NZ602161A patent/NZ602161A/en unknown
- 2011-03-01 CN CN201180022024.1A patent/CN102892426B/zh active Active
- 2011-03-04 TW TW103119822A patent/TWI551611B/zh active
- 2011-03-04 TW TW105139338A patent/TWI646110B/zh active
- 2011-03-04 TW TW100107346A patent/TWI551296B/zh active
- 2011-03-04 TW TW104144118A patent/TWI639441B/zh active
- 2011-03-04 TW TW105139339A patent/TWI645858B/zh active
- 2011-03-04 TW TW102134185A patent/TWI645857B/zh active
- 2011-03-05 SA SA114350709A patent/SA114350709B1/ar unknown
- 2011-03-06 JO JOP/2011/0078A patent/JO3538B1/ar active
-
2012
- 2012-08-30 CR CR20120450A patent/CR20120450A/es unknown
- 2012-08-31 ZA ZA2012/06556A patent/ZA201206556B/en unknown
- 2012-09-03 CL CL2012002433A patent/CL2012002433A1/es unknown
- 2012-09-03 TN TNP2012000437A patent/TN2012000437A1/en unknown
- 2012-09-04 IL IL221767A patent/IL221767B/en active IP Right Grant
- 2012-09-04 EC ECSP12012139 patent/ECSP12012139A/es unknown
- 2012-09-04 HN HN2012001846A patent/HN2012001846A/es unknown
- 2012-09-28 CO CO12170684A patent/CO6630123A2/es not_active Application Discontinuation
-
2013
- 2013-01-11 HK HK16109263.3A patent/HK1221154A1/zh unknown
-
2015
- 2015-06-01 US US14/727,032 patent/US9714295B2/en active Active
- 2015-06-01 US US14/727,135 patent/US9714296B2/en active Active
-
2016
- 2016-02-04 CL CL2016000284A patent/CL2016000284A1/es unknown
- 2016-08-29 JP JP2016166835A patent/JP6294414B2/ja active Active
-
2017
- 2017-06-19 US US15/626,709 patent/US10683364B2/en active Active
-
2018
- 2018-08-20 CL CL2018002380A patent/CL2018002380A1/es unknown
- 2018-08-20 CL CL2018002383A patent/CL2018002383A1/es unknown
-
2019
- 2019-08-14 CY CY20191100876T patent/CY1121913T1/el unknown
- 2019-08-16 HR HRP20191483 patent/HRP20191483T1/hr unknown
-
2020
- 2020-05-07 US US16/868,927 patent/US20200377612A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221154A1 (zh) | 反應性的抗體、其免疫學活性片段及其用途 | |
EP2581156A4 (en) | BINDER FOR SINGING LOW TEMPERATURE SINK, AND BONDING METHOD USING THE BINDER | |
GB201115529D0 (en) | Antibodies, uses and methods | |
GB201115280D0 (en) | Antibodies, uses and methods | |
IL222930A0 (en) | Chlorotoxin variants, conjugates and methods for their use | |
EP2525813A4 (en) | ANTIBODIES TO ILT5 AND ILT5 BINDING ANTIBODY FRAGMENTS | |
RS62700B1 (sr) | Anti-cd277 antitela i njihove upotrebe | |
KR101882034B1 (ko) | 금속화를 위한 방법들, 디바이스들 및 재료들 | |
EP2632949A4 (en) | SPECIFIC ANTIBODIES OF DIFFICULT CLOSTRIDIUM AND THEIR APPLICATIONS | |
HK1179981A1 (zh) | 的抗體及其用途 | |
ZA201302537B (en) | Stable and soluble antibodies | |
EP2571982A4 (en) | ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS | |
SG10201501285RA (en) | Anti-alpha2 integrin antibodies and their uses | |
EP2632952A4 (en) | ANTI-SOD1 ANTIBODIES AND USES THEREOF | |
ZA201406381B (en) | Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof | |
EP2557620A4 (en) | ACTIVE MATERIAL FOR ONE BATTERY AND BATTERY | |
EP2594281A4 (en) | INSULIN LIPID COMPLEX, MANUFACTURING METHOD AND PREPARATION THEREFROM | |
EP2562197A4 (en) | Copolymer comprising anthracene and benzoselenadiazole, preparing method and uses thereof | |
EP2580231A4 (en) | PEPTIDES, CONSTRUCTIONS AND USES THEREOF | |
EP2660264A4 (en) | PHOTOVOLTAIC POLYMER MATERIAL, METHOD FOR THE PRODUCTION AND USE THEREOF | |
PL2577839T3 (pl) | Urządzenie bilansujące, zasobnik energii oraz sposób bilansowania | |
EP2555303A4 (en) | BINDER MATERIAL FOR FUEL CELL, AND FUEL CELL | |
EP2545378A4 (en) | ANTI-LG3 ANTIBODIES AND USES THEREOF | |
EP2607447A4 (en) | BORATE-BASED LUMINESCENT MATERIALS, PREPARATION METHODS AND USES THEREOF | |
PL393196A1 (pl) | Biokatoda, sposób wykonania biokatody i ogniwo cynkowo-tlenowe obejmujące biokatodę |